This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Odonate Therapeutics Past Earnings Performance
Past criteria checks 0/6
Key information
16.3%
Earnings growth rate
30.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -143.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2021 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Odonate Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 21 | 0 | -102 | 9 | 71 |
| 30 Jun 21 | 0 | -119 | 11 | 97 |
| 31 Mar 21 | 0 | -130 | 10 | 120 |
| 31 Dec 20 | 0 | -126 | 10 | 117 |
| 30 Sep 20 | 0 | -122 | 11 | 113 |
| 30 Jun 20 | 0 | -118 | 11 | 110 |
| 31 Mar 20 | 0 | -113 | 11 | 105 |
| 31 Dec 19 | 0 | -112 | 11 | 104 |
| 30 Sep 19 | 0 | -113 | 11 | 105 |
| 30 Jun 19 | 0 | -110 | 11 | 102 |
| 31 Mar 19 | 0 | -101 | 11 | 92 |
| 31 Dec 18 | 0 | -89 | 11 | 80 |
| 30 Sep 18 | 0 | -76 | 11 | 66 |
| 30 Jun 18 | 0 | -62 | 9 | 54 |
| 31 Mar 18 | 0 | -47 | 7 | 40 |
| 31 Dec 17 | 0 | -33 | 5 | 28 |
| 30 Sep 17 | 0 | -19 | 2 | 17 |
| 30 Jun 17 | 0 | -10 | 1 | 8 |
| 31 Mar 17 | 0 | -6 | 1 | 5 |
| 31 Dec 16 | 0 | -3 | 0 | 3 |
Quality Earnings: 4OD is currently unprofitable.
Growing Profit Margin: 4OD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 4OD's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 4OD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4OD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.2%).
Return on Equity
High ROE: 4OD has a negative Return on Equity (-143.01%), as it is currently unprofitable.